Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/Rilonacept> ?p ?o }
Showing triples 1 to 69 of
69
with 100 triples per page.
- Rilonacept abstract "Rilonacept, also known as IL-1 Trap (marketed by Regeneron Pharmaceuticals under the trade name Arcalyst), is an interleukin 1 inhibitor.Rilonacept is a dimeric fusion protein consisting of the ligand-binding domains of the extracellular portions of the human interleukin-1 receptor component (IL-1R1) and IL-1 receptor accessory protein (IL-1RAcP) linked in-line to the fragment-crystallizable portion (Fc region) of human IgG1 that binds and neutralizes IL-1.Rilonacept was given an \"Orphan Drug\" status by the United States Food and Drug Administration and is used for the treatment of cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome, Muckle-Wells syndrome and neonatal onset multisystem inflammatory disease(not approved in the U.S. on this indication).On May 8th, 2012 an FDA Advisory Panel voted 11-0 against the approval of rilonacept for the treatment of gout, stating that the benefits did not outweigh the risks associated with the drug.".
- Rilonacept atcPrefix "L04".
- Rilonacept atcSuffix "AC04".
- Rilonacept fdaUniiCode "8K80YB5GMG".
- Rilonacept iupacName "n/a".
- Rilonacept wikiPageExternalLink www.regeneron.com.
- Rilonacept wikiPageID "16305376".
- Rilonacept wikiPageLength "3118".
- Rilonacept wikiPageOutDegree "13".
- Rilonacept wikiPageRevisionID "691443431".
- Rilonacept wikiPageWikiLink Category:Engineered_proteins.
- Rilonacept wikiPageWikiLink Category:Immunosuppressants.
- Rilonacept wikiPageWikiLink Cold_urticaria.
- Rilonacept wikiPageWikiLink Cryopyrin-associated_periodic_syndrome.
- Rilonacept wikiPageWikiLink Food_and_Drug_Administration.
- Rilonacept wikiPageWikiLink Fragment_crystallizable_region.
- Rilonacept wikiPageWikiLink Fusion_protein.
- Rilonacept wikiPageWikiLink Interleukin-1_family.
- Rilonacept wikiPageWikiLink Muckle–Wells_syndrome.
- Rilonacept wikiPageWikiLink Neonatal_onset_multisystem_inflammatory_disease.
- Rilonacept wikiPageWikiLink Orphan_drug.
- Rilonacept wikiPageWikiLink United_States.
- Rilonacept wikiPageWikiLinkText "Rilonacept".
- Rilonacept wikiPageWikiLinkText "rilonacept".
- Rilonacept atcPrefix "L04".
- Rilonacept atcSuffix "AC04".
- Rilonacept chembl "1201830".
- Rilonacept chemspiderid "none".
- Rilonacept iupacName "n/a".
- Rilonacept legalUs "Rx-only".
- Rilonacept licenceUs "Arcalyst".
- Rilonacept pregnancyUs "C".
- Rilonacept routesOfAdministration "Subcutaneous".
- Rilonacept unii "8".
- Rilonacept verifiedfields "changed".
- Rilonacept verifiedrevid "464382495".
- Rilonacept wikiPageUsesTemplate Template:Antineoplastic-drug-stub.
- Rilonacept wikiPageUsesTemplate Template:Cascite.
- Rilonacept wikiPageUsesTemplate Template:Chemspidercite.
- Rilonacept wikiPageUsesTemplate Template:Drugbankcite.
- Rilonacept wikiPageUsesTemplate Template:Drugbox.
- Rilonacept wikiPageUsesTemplate Template:Drugs.com.
- Rilonacept wikiPageUsesTemplate Template:Ebicite.
- Rilonacept wikiPageUsesTemplate Template:Fdacite.
- Rilonacept wikiPageUsesTemplate Template:Immunosuppressants.
- Rilonacept wikiPageUsesTemplate Template:Reflist.
- Rilonacept subject Category:Engineered_proteins.
- Rilonacept subject Category:Immunosuppressants.
- Rilonacept hypernym Rilonacept.
- Rilonacept type ChemicalSubstance.
- Rilonacept type Drug.
- Rilonacept type Chemical.
- Rilonacept type Drug.
- Rilonacept type Immunosuppressant.
- Rilonacept type Redirect.
- Rilonacept type ChemicalObject.
- Rilonacept type Thing.
- Rilonacept type Q8386.
- Rilonacept comment "Rilonacept, also known as IL-1 Trap (marketed by Regeneron Pharmaceuticals under the trade name Arcalyst), is an interleukin 1 inhibitor.Rilonacept is a dimeric fusion protein consisting of the ligand-binding domains of the extracellular portions of the human interleukin-1 receptor component (IL-1R1) and IL-1 receptor accessory protein (IL-1RAcP) linked in-line to the fragment-crystallizable portion (Fc region) of human IgG1 that binds and neutralizes IL-1.Rilonacept was given an \"Orphan Drug\" status by the United States Food and Drug Administration and is used for the treatment of cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome, Muckle-Wells syndrome and neonatal onset multisystem inflammatory disease(not approved in the U.S. ".
- Rilonacept label "Rilonacept".
- Rilonacept sameAs Q7334300.
- Rilonacept sameAs ريلوناسيبت.
- Rilonacept sameAs Rilonacept.
- Rilonacept sameAs m.03wghqq.
- Rilonacept sameAs Rilonacept.
- Rilonacept sameAs Rilonacept.
- Rilonacept sameAs Q7334300.
- Rilonacept wasDerivedFrom Rilonacept?oldid=691443431.
- Rilonacept isPrimaryTopicOf Rilonacept.